Verona Pharma can take its asthma and fever treatment to its next trial phase after approval by the Netherlands Ethics Committee.
A clinical update from the AIM-quoted company says its RPL554 treatment can now go to the final stage of its Phase I/IIa clinical trial. Analysts suggest London-based Verona should be well placed to have RPL554 licensed if it successfully completes this trial.
Verona, which seeks to research, discover and develop new therapeutic drugs for hay fever, asthma and and other chronic respiratory diseases, has been conducting the RPL554 trials at the Centre for Human Drug Research at Leiden in Holland. Not wanting to have all its eggs in one basket, the company is also working on another project, ‘Novel Anti-Inflammatory Polysaccharides’, to develop a new anti-inflammatory drug.
As a drug discoverer, profits have so far eluded Verona, chaired by Professor Clive Page and steered by chief executive officer Dr Clive Walker. The company lost £1.3m last year, but, after raising £2.3m at 4p, ended 2008 with £2.5m cash.
Shares in Verona, floated four years ago at 2p, reached 6.25p in 2007 before crumbling to 2.13p by last August. Tipped by Growth Company Investor at 4.12p, they have since rallied 40% to 6.62p, and could make further progress if clinical developments go well.
Market cap: £14.25m
PE Forecast: n/a
Share price: 6.62p
£7,277 That’s what you would have in your portfolio if you had invested £6,000 into the six Company Watch recommendations in our April 2009 issue.
Advertisement
Growth Company Investor, in association with the London Stock Exchange, presents the most wide-ranging and detailed examination of the AIM market: AIM in Review 2010. For more information and to order, click here or contact our marketing team on 020 7250 7056.
M&A on AIM 2009 is a unique and wide-ranging examination of merger and acquisition activity on AIM over the past 12 months, with an analysis of all the acquisitions, disposals, takeovers and delistings on AIM, including
canvassing the opinions of some of the major M&A powerbrokers. To order click here.
Free access to the latest AIM stock recommendations and news from the award-winning Growth Company Investor team. Receive our tips on what stocks to buy direct to your inbox every Tuesday and Friday. Find out more today.
Cautious? Positive? Adventurous? Choose between three levels of risk for a fund of funds from Sharefunds, our sister company. Click here for more information.
The brand new, fully updated AIM Guide 2009/2010 is now available to purchase. AIM Guide is the only fully comprehensive guide to AIM and is regarded as 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today and benefit from a £10 discount!
This report's principal aim is to provide business owners seeking funding with information about the amount of funds that VCTs have to invest. Click here for more information.
Business XL, the award-winning monthly magazine for growing companies, is delighted to announce the launch of a new study on cash shells. The research provides a comprehensive overview of cash shells on AIM, companies that have become a significant feature on the AIM landscape. Buy the Cash Shells 2009 Research Report today or email Halid Delkic to obtain a free two-page abstract.
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Advertisement
Having navigated its way through a testing first half of 2009, international software testing specialist SQS then experienced a dramatic second half upswing in fortunes.
In the midst of a pleasing turnaround, performance improvement technology group eg solutions has also completed a strategically astute-looking bolt-on acquisition.
Highly resilient outsourced human resources specialist Staffline grew its profits in a grim 2009 for the recruitment industry.